The answer: alternative splicing. A critical finding regarding ... the CaMK IV-mediated signaling pathway leading to skipping of the STREX exon (Shin & Manley 2004, Figure 5).
Clinical Trials Arena on MSN9d
FDA removes clinical hold on Entrada’s Duchenne therapyEntrada Therapeutics can plough on with the development of its Duchenne muscular dystrophy (DMD) therapy, ENTR-601-44, now ...
Hosted on MSN2mon
SPLICER shows promise in Alzheimer's and other diseasesSPLICER uses a gene editing approach called exon skipping, which is of particular interest for health conditions caused by mutations that produce misfolded or toxic proteins, such as Duchenne's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback